References
Targan SR, Hanauer SB, Van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schible TF, Rutgeerts PJ (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. N Engl J Med 337:1029–1035
Nugent WF, Roy MZ (1986) Duodenal Crohn’s disease: an analysis of 89 cases. Am J Gastroenterol 89:249–254
D’Haens G, Van Deventer SJ, Van Hoegezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P (1999) Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: A European multicenter trial. Gastroenterology 116:1029–1034
DiSabatino A, Ciccocioppo R, Benazzato L, Sturniolo GC, Corazza GR (2004) Infliximab down-regulates basic fibroblast growth factor and vascular endothelial growth factor in Crohn’s disease patients. Aliment Pharmacol Ther 19:1019–1024
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Odashima, M., Otaka, M., Jin, M. et al. Successful Treatment of Refractory Duodenal Crohn’s Disease with Infliximab. Dig Dis Sci 52, 31–32 (2007). https://doi.org/10.1007/s10620-006-9585-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-006-9585-3